- Companies
- ReMix Therapeutics
ReMix Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for ReMix Therapeutics.
ReMix Therapeutics Overview
About ReMix Therapeutics
ReMix Therapeutics Inc is a clinical-stage biotechnology company focused on developing small molecule therapeutics to modulate ribonucleic acid (RNA) processing and address the underlying drivers of disease. Its flagship program, REM-422, is an investigational oral mRNA degrader targeting the MYB oncogenic transcription factor, which is being developed for the treatment of adenoid cystic carcinoma (ACC), acute myelogenous leukemia (AML), myelodysplastic syndromes (MDS), and other cancers.
Founded
2019
HQ
Employees
37
Website
Financials (Last FY)
Market Cap
-
Valuation Multiples
Start free trialReMix Therapeutics Stock Performance
ReMix Therapeutics has current market cap of -.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| - | - | - | - | - | - |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialReMix Therapeutics Valuation Multiples
ReMix Therapeutics Financial Valuation Multiples
As of November 10, 2026, ReMix Therapeutics has market cap of -.
| LTM | Last FY | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified ReMix Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


ReMix Therapeutics Competitors
ReMix Therapeutics competitors include Eli Lilly, Johnson & Johnson, AbbVie, Roche, Merck, Novartis, AstraZeneca, Amgen, Gilead Sciences and Novo Nordisk.
Most ReMix Therapeutics public comparables operate across Biopharmaceuticals, Diagnostics & Genomics, BioTech and DeepTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $65B | $28B | 20.0x | 14.9x | 47.0x | 31.3x | |||
| $94B | $40B | 7.5x | 7.0x | 17.7x | 19.2x | |||
| $61B | $17B | 9.6x | 8.8x | 33.9x | 18.7x | |||
| $77B | $26B | 5.5x | 5.4x | 16.1x | 13.6x | |||
| $65B | $28B | 6.3x | 6.1x | 14.7x | 23.3x | |||
| $57B | $22B | 6.1x | 6.1x | 15.9x | 14.9x | |||
| $59B | $19B | 5.4x | 5.1x | 16.5x | 14.1x | |||
| $37B | $17B | 8.0x | 7.5x | 17.4x | 16.6x | |||
This data is available for Pro users. Sign up to see all ReMix Therapeutics competitors and their valuation data. Start Free Trial | ||||||||
ReMix Therapeutics VC Funding History
Before going public, ReMix Therapeutics raised $211M in total equity funding, across 4 rounds.
ReMix Therapeutics Funding Rounds
Acquisitions by ReMix Therapeutics
ReMix Therapeutics has acquired 1 company to date.
Last acquisition by ReMix Therapeutics was on June 23rd 2026. ReMix Therapeutics acquired Passage Bio for undisclosed valuation.
Latest Acquisitions by ReMix Therapeutics
| Description | Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases. |
| HQ Country | |
| HQ City | Philadelphia, PA |
| Deal Date | 23 Jun 2026 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all ReMix Therapeutics acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout ReMix Therapeutics
| When was ReMix Therapeutics founded? | ReMix Therapeutics was founded in 2019. |
| Where is ReMix Therapeutics headquartered? | ReMix Therapeutics is headquartered in United States. |
| How many employees does ReMix Therapeutics have? | As of today, ReMix Therapeutics has over 37 employees. |
| Is ReMix Therapeutics publicly listed? | Yes, ReMix Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of ReMix Therapeutics? | ReMix Therapeutics trades under RMTX ticker. |
| When did ReMix Therapeutics go public? | ReMix Therapeutics went public in 2050. |
| Who are competitors of ReMix Therapeutics? | ReMix Therapeutics main competitors include Eli Lilly, Johnson & Johnson, AbbVie, Roche, Merck, Novartis, AstraZeneca, Amgen, Gilead Sciences, Novo Nordisk. |
| Is ReMix Therapeutics profitable? | No, ReMix Therapeutics is not profitable. |
| How many companies ReMix Therapeutics has acquired to date? | As of November 2026, ReMix Therapeutics has acquired 1 company. |
| What was the largest acquisition by ReMix Therapeutics? | None of the M&A deals ReMix Therapeutics has completed have disclosed valuations. |
| What companies ReMix Therapeutics acquired? | ReMix Therapeutics acquired Passage Bio. |
| In how many companies ReMix Therapeutics has invested to date? | ReMix Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to ReMix Therapeutics
Lists including ReMix Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




